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morbidity,	 mortality	 and	 global	 economic	 burden.	 The	 universally	 used	 bacterial	4 
genotyping	 methods	 are	 Multi‐Locus	 Sequence	 Typing	 (MLST)	 and	 Pulsed	 Field	 Gel	5 
Electrophoresis	 (PFGE).	 However,	 another	 highly	 discriminatory,	 rapid	 and	 less	6 
expensive	 genotyping	 technique,	 Multi‐Locus	 Variable	 Number	 of	 Tandem	 Repeat	7 
Analysis	 (MLVA),	 has	 been	 developed.	 Unfortunately,	 no	 universal	 MLVA	 protocol	8 
exists,	 and	 some	 MLVA	 protocols	 do	 not	 amplify	 certain	 loci	 for	 all	 pneumococcal	9 
serotypes,	 leaving	 genotyping	 profiles	 incomplete.	 A	 number	 of	 other	 genotyping	 or	10 







S.	 pneumoniae	 is	 a	 potentially	 deadly	 human	 pathogen	 associated	 with	 high	18 
morbidity	(estimated	14.5	million	episodes	of	serious	pneumococcal	disease		in	the	year	19 
2000),	high	mortality	(causes	11%	of	deaths	in	children	aged	under	five	years)	and	high	20 
economic	 burden	 globally,	 especially	 in	 underdeveloped	 countries	 [1].	 Since	 the	21 
introduction	 of	 a	 childhood	 pneumococcal	 vaccine	 (7‐valent	 Pneumococcal	 Conjugate	22 
Vaccine;	 7vPCV:	 Wyeth),	 serotype	 replacement	 of	 targeted	 pneumococcal	 serotypes	23 
with	 non‐targeted	 pneumococcal	 serotypes	 have	 almost	 countermanded	 the	 effect	 of	24 
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polysaccharide	 capsule	with	other	pneumococci,	 enabling	both	 to	 carry	a	non‐vaccine	26 
targeted	 capsule	 and	 become	 immune	 to	 the	 vaccines,	 leading	 to	 “vaccine‐escape”	27 
strains	[4‐6].	As	of	December	2012,	a	total	of	86	(44%)	WHO	member	states	have	added	28 
a	 PCV	 to	 their	 routine	 infant	 immunization	 schedule	 of	 the	 national	 immunization	29 
programmes	[7].		30 
Characterisation	 of	 bacteria	 below	 the	 species	 level	 using	 sub‐typing	methods	31 
enable	 the	 assessment	 of	 the	 impact	 of	 human	 interventions	 such	 as	 vaccines	 and	32 
antibiotics,	 the	 	 relatedness	 of	 bacterial	 isolates,	 and	 the	 sources	 and	 transmission	33 
routes	 of	 infections	 [8].	 Traditional	 characterisation	 sub‐typing	 techniques,	 such	 as	34 
Quellung	serotyping,	has	been	used	for	decades	in	pneumococcal	epidemiology	studies	35 
[9].	 Unfortunately,	 only	 95	 published	 serotypes	 can	 be	 determined	 (compared	 to	36 
thousands	of	genotypes	identified	within	these	95	serotypes),	not	all	serotypes	can	be	37 
distinguished	 (serotype	 6A	 and	 6C	 are	 distinguished	 through	 PCR),	 and	 capsule	38 
switching	 cannot	 be	 detected	 without	 the	 assistance	 of	 a	 genotyping	 method.	 The	39 






discriminatory	 power,	 good	 resolution	 and	 good	 reproducibility;	 however	 limitations	46 
still	 remain.	MLVA	 is	 another	 promising	 genotyping	method.	Unfortunately,	 there	 are	47 
many	different	MLVA	protocols	for	S.	pneumoniae,	and	limitations	have	been	identified	48 
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[9],	mass‐spectrometry	 [26‐27],	 and	Next	 Generation	 Sequencing	 (NGS)	 [28‐29].	 This	50 




Traditional	 characterisation	 methods	 for	 epidemiology	 studies,	 such	 as	55 
serotyping	 (Quellung	 or	 Neufeld),	 only	 provides	 a	 broad	 picture	 of	 changes,	 	 cannot	56 
differentiate	 genotypes	 or	 capsule	 switching,	 and	 is	 restricted	 to	 large	 reference	57 
laboratories	 due	 to	 costs	 and	 availability	 of	 specific	 reagents	 [30].	 In	 the	 Quellung	58 
reaction,	 antibodies	 bind	 and	 react	 to	 the	 pneumococcal	 polysaccharide	 capsule,	59 
causing	 it	 to	 become	 opaque	 and	 enlarged	 when	 visualised	 under	 a	 microscope	 [9].	60 
However,	phenotypic	variations	of	the	polysaccharide	capsule	do	not	necessarily	reflect	61 
genetic	 variations	 because	 external	 influences	 can	 change	 the	 phenotype	 [10].	62 
Therefore	 a	 number	 of	 PCR	 based	 serotyping	 methods	 have	 been	 developed	 for	 S.	63 
pneumoniae	 [31‐44].	 Despite	 numerous	 PCR	 based	 serotyping	methods,	 the	 Quellung	64 
reaction	has	remained	as	the	“gold	standard”	characterisation	technique.	Unfortunately,	65 
it	 is	 also	 commonly	 the	 sole	 sub‐typing	method	 used	 in	 pneumococcal	 epidemiology	66 
studies,	thus	posing	limitations	on	the	comprehension	of	the	relatedness	between	two	67 
invasive	 isolates	 at	 the	 genetic	 level,	 identifying	 specific	 sources	 of	 infections	 (apart	68 
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an	association	which	aims	 to	 survey	 the	global	 antibiotic	 resistant	S.	pneumoniae	and	76 
standardise	 nomenclature	 and	 classification	 of	 resistant	 clones	77 
(web1.sph.emory.edu/PMEN/)	 (45).	 Developed	 by	 Enright	 and	 Spratt	 [17],	 there	 are	78 






MLST	 utilizes	 seven	 housekeeping	 genes	 (aroE,	 gdh,	 gki,	 recP,	 spi,	 xpt	 and	 ddl)	 to	85 
genotype	S.	pneumoniae	[17].	Housekeeping	genes	are	considered	stable	and	less	prone	86 
to	 recombination	 than	 other	 regions	 of	 the	 S.	 pneumoniae	 genome	 [17].	 These	87 
conserved	 regions	 are	 considered	 more	 appropriate	 for	 evolutionary	 rather	 than	88 
epidemiology	studies	where	frequently	changing	genomic	regions,	such	as	those	used	in	89 
MLVA,	are	more	desirable	 [30].	A	 fluorescent	 label	 is	 incorporated	 into	PCR‐amplified	90 
housekeeping	 genes	 for	 sequencing.	 Single	 nucleotide	 polymorphisms	 (SNPs)	91 
distinguish	 alleles	 and	 a	 sequence	 type	 (ST)	 is	 generated	 from	 the	 combined	 seven	92 
alleles.	 Unfortunately,	 MLST	 also	 poses	 limitations	 including	 the	 high	 expense	 to	93 
genotype,	 especially	 when	 examining	 large	 batches	 of	 isolates,	 it	 is	 technically	94 
demanding	with	several	PCR	steps,	DNA	purification	steps	and	sequencing	analysis,	and	95 
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it	 has	 not	 been	 developed	 for	 routine	 use	 despite	 automation	 [20,	 23,	 51‐53].	 Data	96 
analysis	can	also	be	laborious	and	can	take	longer	than	the	analysis	of	MLVA	data	[30].	97 
On	 the	 other	 hand,	 PFGE	 has	 higher	 discriminatory	 power	 than	 MLST,	 good	98 
resolution	 and	 good	 typeability	 [17,	 23,	 47‐48].	 	 PFGE	 was	 faster	 and	 more	99 
discriminatory	 than	MLEE,	 prompting	 its	wide	 use	 before	MLST	was	 developed	 [54].	100 
Restriction	 enzymes	 are	 used	 to	 digest	 genomic	 DNA	 of	 S.	 pneumoniae	 into	 large	101 
fragments	which	are	separated	by	pulsed	gel	electrophoresis;	the	DNA	banding	patterns	102 
(fingerprints)	are	then	compared	between	isolates	[18,	52].	PFGE	is	listed	as	a	standard	103 
genotyping	 method	 by	 PMEN.	 However,	 it	 would	 no	 longer	 be	 considered	 a	 ‘gold	104 
standard’	genotyping	method	for	S.	pneumoniae	considering	the	small	size	and	quality	105 
of	 the	 database	 in	 comparison	 to	 the	 international	 MLST	 database,	 the	 lack	 of	 a	106 
universal	 and	 generally	 accepted	 scheme,	 the	 fact	 that	 PFGE	 suffers	 from	 lack	 of	107 
portability	between	laboratories	unless	standardised,	is	ambiguous,	is	not	amenable	for	108 
international	 database,	 is	 laborious	 and	 poses	 a	 potential	 health	 hazard	 through	109 
prolonged	handling	of	 cultivable	 strains	 [23,	 51,	 55‐56].	As	 a	 results,	MLST	became	a	110 
more	popular	genotyping	method.	Even	MLVA	can	be	more	discriminatory	than	PFGE,	111 
where	 four	 to	 five	 highly	 variable	 genomic	 regions	 have	 been	 used	 to	 characterise	112 
Salmonella	enterica	serovar	Typhimurium	infections	[24].	113 
Despite	 the	 popularity	 of	 MLST,	 researchers	 have	 still	 been	 testing	 for	114 
improvements,	 particularly	 to	 minimise	 technical	 requirements,	 cost	 and	 laboratory	115 
work.	Methods	that	are	relatively	cheap	and	applicable	in	standard	procedures	on	mass	116 
scale	 are	 more	 desired	 than	 expensive	 technology	 with	 high	 differentiation	 [30].	117 
Crisafulli	et	al.	[57]	developed	an	alternative	MLST	method	which	utilises	96	loci	(rather	118 
than	seven)	based	on	39	complete	S.	pneumoniae	genomes.	By	increasing	the	number	of	119 
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loci,	 strains	with	 the	 same	ST	but	different	 capsule	 types	 can	be	differentiated,	 and	 a	120 
higher	discrimination	and	better	 resolution	can	be	achieved.	However,	 sequencing	96	121 
loci	is	quite	laborious,	as	their	method	indicates	that	each	isolate	requires	a	full	96‐well	122 
plate	to	obtain	a	complete	profile;	consequently,	only	69	isolates	were	sequenced.	This	123 
paper	claims	 that	 the	96‐MLST	could	still	be	applicable	as	a	high‐throughput	method,	124 
even	in	small	scale	laboratories,	with	costs	per	isolate	comparable	with	NGS	methods.	It	125 




With	 the	 advancement	 of	 NGS	 technology,	 a	 number	 of	 protocols	 combining	130 
MLST	with	NGS	have	been	published.	MLST	has	been	modified	by	Boers	et	al.	[28]	who	131 
incorporated	 NGS	 technology	 such	 as	 the	 Roche	 454	 sequencing	 to	 provide	 a	 high‐132 
throughput	MLST	(HiMLST)	method.	HiMLST	attaches	a	unique	DNA	barcode	called	the	133 
multiplex	 identifier	 (MID),	 allowing	 the	 combination	 of	 multiple	 species	 of	 bacteria.	134 
They	 have	 simultaneously	 sequenced	 Legionella	 pneumophila,	 Staphylococcus	 aureus,	135 
Pseudomonas	aeruginosa	and	Streptococcus	pneumoniae	 [28].	HiMLST	provides	a	high‐136 
throughput	 and	 cost	 effective	modification	of	MLST	 (ten	 fold	 reduction	 in	 costs	using	137 
HiMLST	method	compared	to	Sanger	sequencing	of	MLST	genes)	especially	if	using	NGS	138 
technology.	 However	 in	 comparison	 to	 current	 MLVA	 techniques,	 HiMLST	 is	 still	139 
expensive	 and	 time	 consuming.	 HiMLST	 could	 be	 adapted	 to	 become	 more	140 
discriminatory	 than	 MLST	 by	 increasing	 the	 number	 of	 targets	 [28].	 A	 similar	 NGS	141 
technique	called	MLST‐seq	uses	species‐specific	hairpin	primers	and	MIDs	to	amplify	20	142 
target	loci	in	Salmonella	enterica	with	Roche	454	sequencing.	Nevertheless,	a	number	of	143 
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Other	 MLST	 genotyping	 techniques	 have	 been	 devised	 utilising	 mass	148 
spectrometry,	which	has	been	reported	to	be	the	“next	generation	tool”	for	identifying	149 
species	 of	 various	 microorganisms	 [59].	 Matrix‐assisted	 laser	 desorption	 ionization	150 
time‐of‐flight	 mass‐spectrometry	 (MALDI‐TOF‐MS)	 has	 been	 used	 to	 identify	 S.	151 
pneumoniae	 species,	as	well	as	characterise	 isolates	 further	using	MLST	housekeeping	152 
genes,	although	there	have	been	reports	that	identification	can	be	difficult	[26,	60‐61].	153 
Papua	 New	 Guinean	 S.	 pneumoniae	 isolates	 were	 genotyped	 using	 cleaved	 MLST	154 
housekeeping	genes	that	had	mass	signal	patterns	analysed	using	MALDI‐TOF‐MS	[26].	155 
This	MS‐based	method	 requires	additional	 sample	preparation;	however	 the	 speed	of	156 
analysis	 allows	 this	 method	 to	 be	 more	 cost‐effective	 than	 MLST.	 MALDI‐TOF‐MS	157 
reported	 99.0%	 concordance	 rate	 with	 MLST	 is	 faster	 and	 more	 cost	 effective	 than	158 
MLST	sequencing	but	manual	inspection	was	required	for	40%	of	total	alleles.		159 
An	 alternative	 genotyping	 method,	 Pneumococcal	 Serotyping	 and	 Genotyping	160 
method	 (PSGS),	 amplifies	 40	 genes	 (32	 serotype‐specific	 genes	 located	 within	 the	161 





difficulty	 to	 produce	 single‐stranded	 products	 in	 gas	 phase	 for	 larger	 fragment	 sizes	167 
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on	 genomic	 sequencing,	 which	 MLST	 currently	 provides	 when	 characterising	 S.	174 
pneumoniae	strains.	However	even	though	the	expensive	cost	and	speed	of	sequencing	175 





alternative	 genotyping	 method	 for	 S.	 pneumoniae.	 MLVA	 is	 claimed	 to	 be	 more	181 
discriminatory	 than	 MLST,	 therefore	 it	 may	 be	 more	 suitable	 for	 local	 outbreaks	 of	182 
diseases	 [8,	22,	63].	However,	since	MLVA	genotyping	 is	not	known	to	be	used	by	 the	183 
PMEN	and	has	only	been	used	by	a	few	research	groups	globally,	MLST	is	currently	used	184 
as	a	comparative	genotyping	method.	185 
MLVA	 amplifies	 Variable	 Number	 of	 Tandem	 Repeats	 (VNTRs)	 instead	 of	186 
housekeeping	genes	to	form	an	allelic	profile	[8].	VNTRs	are	preferred	for	epidemiology	187 
studies	 and	outbreaks	due	 to	 the	high	 variability	 in	 the	 genes.	However	 this	 can	 also	188 
lead	to	instability	of	some	loci,	therefore	it	has	been	recommended	that	further	studies	189 
are	 required	 to	 thoroughly	 understand	 these	 mutations	 and	 mutation	 rates	 [30].	190 
Multiplexing	with	fluorescent	labels	can	be	utilised	and	PCR	products	are	separated	by	191 
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allele	 type	 (Table	 1)	 [8].	 Using	 capillary	 electrophoresis	 enables	 automation	 and	 a	193 
higher	 throughput	with	 the	use	of	an	 internal	 size	 ladder	 for	accurate	sizing	 [8].	 	 It	 is	194 
unknown	 whether	 VNTRs	 are	 under	 neutral	 or	 positive	 selection,	 however	195 
environmental	 influences	 can	 affect	 the	 speed	 of	 VNTR	 changes	 [64].	 Recombination	196 
rates	 in	 pneumococci	 are	 high	 [66].	 VNTRs	 are	 polymorphic,	 making	 them	 “suitable	197 
target(s)	 for	 assessing	 genetic	 polymorphism(s)	 within	 bacterial	 species”	 [20,	 56].	198 
MLVA	 has	 been	 applied	 to	many	 bacteria	 including	Bacillus	anthracis,	 Staphylococcus	199 
aureus,	Yersinia	pestis,	Salmonella	typhi	and	Escherichia	coli	O157	[23,	52,	56].		200 
The	 original	 MLVA	 protocol	 for	 S.	 pneumoniae	 included	 amplifying	 seventeen	201 
VNTRs	[20].	This	method	has	been	used	to	genotype	48	isolates	 in	Burkina	Faso	from	202 




Another	MLVA	 technique	was	developed	by	Elberse	et	al.	 [8]	which	used	eight	207 
BOX	 loci	 selected	 from	 an	 original	 thirteen	 randomly	 selected	 BOX	 loci	 from	 the	 S.	208 
pneumoniae	R6	 genome.	 BOX	 elements	 are	 VNTRs	 found	within	 intergenic	 regions	 of	209 
the	S.	pneumoniae	genome,	 consisting	 of	 three	 segments:	boxA	 (59	nucleotides),	boxB	210 
(45	nucleotides)	and	boxC	 (50	nucleotides),	with	boxB	 containing	tandem	repeats	[51,	211 
67].	BoxA	and	boxC	are	highly	conserved	between	multiple	species	of	bacteria	however	212 
boxB	 is	 only	observed	 in	S.	pneumoniae	 [9,	 67‐69].	BOX	 loci	have	varying	numbers	of	213 
repeat	regions	e.g.	BOX‐04	has	the	highest	reported	variation	in	repeat	numbers	(0‐17)	214 
whilst	 BOX‐11	 has	 the	 lowest	 variation	 (1‐2),	 allowing	 for	 high	 polymorphism	 and	215 
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loop	 structures	 and	 most	 are	 located	 near	 virulence	 genes	 (neuA	 and	 ply)	 or	217 
transformative	genes,	indicating	they	could	be	regulatory	elements	[8,	21,	67].		218 
Elberse’s	 MLVA	 include	 BOX‐01	 (Spneu40),	 BOX‐02	 (Spneu32),	 BOX‐03	219 
(Spneu15),	BOX‐04a,	BOX‐04b	(Spneu33),	BOX‐06a,	BOX‐06b	(Spneu38),	BOX‐11,	BOX‐220 
12	 (Spneu37)	 and	 BOX‐13	 (Spneu25),	 and	 are	 amplified	 in	 two	multiplex	 PCRs	with	221 
fluorescently	labelled	probes	(FAM,	NED,	VIC	and	PET)	and	sized	on	an	automated	DNA	222 
sequencer	 [8,	 37,	 70].	 This	method	has	 been	 standardised	 so	 that	 different	 platforms	223 
produce	 comparable	 results	 [8,	 30].	MLVA	 standardisation	 for	Shigella	 sonnei	utilised	224 
calibration	 strains	 and	 has	 been	 implemented	 to	 participating	 laboratories	 for	 data	225 
normalisation	 [25,	 71].	 Elberse’s	MLVA	 has	 been	 applied	 to	 1154	 isolates	 of	 invasive	226 
pneumococci	in	the	Netherlands,	which	correlated	to	444	MLVA	types	of	S.	pneumoniae.	227 
Pichon	et	al.	[21]	was	able	to	determine	nine	distinct	MLVA	types	of	serotype	5,	which	228 
were	 associated	 with	 three	 MLST	 types,	 highlighting	 that	 MLVA	 has	 higher	229 
discriminator	 power.	 Elberse	 et	 al.	 [8]	 has	 claimed	 that	 their	 MLVA	 with	 eight	 loci	230 
provides	 high	 resolution	 and	 have	 high	 congruence	 with	 MLST,	 and	 is	 more	 time	231 
efficient	and	less	laborious	than	Koeck’s	17	singleplex	MLVA	(Table	2).	232 
Unfortunately,	 Elberse’s	 results,	 published	 on	 the	 MLVA	 database	233 
(http://www.mlva.net/)	 contained	 many	 typing	 failures	 which	 were	 assigned	 ‘99’	234 
where	 no	 PCR	 amplification	 was	 observed	 (72).	 Examination	 of	 the	 MLVA	 database	235 
reveals	 that	36.5%	MLVA	profiles	(530/1450)	contain	at	 least	one	un‐amplified	 locus,	236 
and	 at	 least	 10%	 of	 profiles	 (146/1450)	 contain	 two	 or	 more	 un‐amplified	 loci.	237 
Similarly,	Koeck’s	MLVA	database	(www.mlva.eu)	also	contains	‘99’	in	some	genotypes	238 
(73).	 Primers	 may	 have	 been	 designed	 for	 universal	 use,	 and	 are	 failing	 to	 amplify	239 
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specific	 serotypes	 e.g.	 BOX‐06	 in	 serotype	 7F	 due	 to	 the	 possibility	 that	 the	 locus	 is	240 
missing	 [70]	 (unpublished	data).	Elberse	et	al.	 [8]	have	already	described	a	 failure	 to	241 
amplify	BOX‐06	 in	89%	of	serotype	7F.	As	such,	 they	have	still	assigned	a	MLVA	type	242 
(MT)	 to	 these	 strains	with	 a	 failed	BOX‐06.	 It	 is	 unknown	whether	 these	 serotype	7F	243 
strains	are	all	genetically	identical	or	whether	some	of	these	strains	may	be	single	locus	244 
variants	 (SLV)	within	BOX‐06.	This	 issue	 remains	unresolved,	 although	 sequencing	of	245 
unusual	 size	 fragments	 have	 been	 reported	 [74].	 As	 there	 are	 127	 BOX	 genes	 in	 S.	246 
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38	(ST393	and	ST310),	which	has	not	been	detected	in	the	UK	study.	 It	 is	known	that	272 
pneumococcal	 populations	 differ	 between	 countries;	 therefore	 the	 selection	 of	 these	273 
seven	MLVA	markers	may	not	be	suitable	 for	other	populations.	Van	Cuyck	et	al.	 [22]	274 
have	 failed	 to	 comment	 on	 the	 non‐amplified	 loci	 observed	 by	 Elberse	 et	 al.	 [8],	275 
particularly	since	three	of	the	VNTRs	selected	are	the	same	as	in	the	Netherlands	study.	276 
Van	Cuyck	et	al.	[22]	have	also	claimed	that	the	ST	and	serotype	can	be	deduced	277 
from	 the	 MLVA	 type,	 depending	 on	 the	 clonality	 of	 the	 serotypes	 without	 actually	278 
having	 to	perform	MLST	or	 serotyping.	This	assumption	may	not	be	applicable	 for	all	279 
serotypes,	 as	 they	 have	 also	 demonstrated	 that	 not	 all	 ST	 of	 serotype	 19F	 could	 be	280 




13)	has	been	 adopted	 in	 all	 the	MLVA	 techniques,	 particularly	 since	 it	 has	one	of	 the	285 
highest	 discriminatory	 power	 (Table	 3).	 Spneu17	 is	 recorded	 with	 the	 highest	286 
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discrimination	 (DI=0.883)	 in	 Koeck	 et	 al.	 [20]	 whilst	 it	 was	 a	 close	 second	 behind	287 
Spneu37	 (BOX‐12)	 in	Van	Cuyck	et	al.	 [22]	 study.	 Elberse	et	al.	 [70]	 also	 described	 a	288 
DI>0.8	for	BOX‐12	however	their	highest	discriminatory	locus	was	BOX‐04	(Spneu33).	289 
The	 locus	 with	 the	 lowest	 discrimination	 varied	 between	 methods	 with	 BOX‐11	290 
(DI=0.460),	 Spneu41	 (DI=0.484)	 or	 Spneu38/BOX‐06	 (DI=0.557).	 It	 appears	 that	 the	291 
discriminatory	 power	 of	 each	 locus	 varies	 slightly	 in	 different	 pneumococcal	292 








Advantages	 of	 genotyping	 S.	 pneumoniae	 with	 MLVA	 include	 that	 it	 is	 more	301 
discriminatory,	 simple,	 fast	 to	 perform,	 less	 expensive	 than	 MLST,	 and	 is	 easily	302 
applicable	 to	 outbreak	 investigations	 [8,	 23,	 56].	 Other	 advantages	 include	 minimal	303 





accepted	 technique.	 This	 has	 limited	 the	 use	 of	 MLVA	 genotyping	 applied	 to	 study	309 
pneumococcal	populations	and	outbreaks.	Comparison	of	current	MLVA	S.	pneumoniae	310 
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	 Other	developed	characterisation	techniques	have	assisted	 in	 the	epidemiology	315 
study	 of	 S.	pneumoniae.	 BOX‐fingerprinting	 uses	 BRA	 and	 BRB	 primers	 to	 generate	 a	316 
151bp	 BOX	 repeat	 gene	 fragment	 in	 the	 S.	pneumoniae	 genome	 [69].	 BOX	 genes	was	317 
shown	to	have	 the	highest	discrimination	compared	to	ribotyping,	PCR	 fingerprinting,	318 
PFGE	 and	 restriction	 fragment	 end	 labelling	 [54].	 However	 BOX‐fingerprinting	 was	319 
quite	laborious	and	required	internal	markers	to	ease	comparison.	320 
	 Finally,	 even	 further	 specific	 characterisation	 techniques	 include	 Penicillin‐321 
binding	protein	typing	[77]	and	Pneumococcal	surface	protein	A	(PspA)	typing	[74‐75].	322 
It	is	important	to	note	that	these	are	not	genotyping	methods	per	se,	but	are	methods	to	323 
further	 understand	 penicillin	 resistance	 and	 antigenicity	 of	 S.	 pneumoniae.	 Penicillin‐324 







Genotyping	methods	used	 for	 typing	S.	pneumoniae	 are	 important	 to	 study	 the	332 
relatedness	 of	 isolates,	 transmission	 routes	 and	 sources	 of	 infectious	 diseases,	 and	333 
assess	 the	 impact	 of	 human	 interventions	 or	 disease	 outcomes.	 Ideally,	 genotyping	334 
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to	 gain	 further	 genetic	 information	 of	 the	 invasive	 strains	 and	 pneumococcal	 isolates	336 
causing	disease.	The	pneumococcus	continues	to	travel	globally	 through	both	carriage	337 
and	 infectious	 disease	 such	 as	 pneumonia.	 Techniques	 with	 high	 throughput,	338 
discrimination,	 typeability	 and	 low	 costs	 are	 deemed	 favourable.	 With	 a	 variety	 of	339 
different	techniques	and	protocols,	it	has	been	shown	that	MLVA	is	emerging	as	a	highly	340 
discriminatory,	 quick	 and	 inexpensive	method	 compared	 to	 the	 currently	 universally	341 
used	MLST.	However	further	study	is	required	to	develop	a	universal	MLVA	technique	342 
since	 current	 protocols	 have	 limitations	 such	 as	 un‐amplified	 loci.	 Unless	 a	 universal	343 
accepted	 method	 is	 developed,	 comparisons	 of	 pneumococcal	 MLVA	 types	 between	344 
countries	 will	 be	 difficult.	 Meanwhile,	 MLST	 remains	 as	 the	 ‘golden	 standard’	345 
genotyping	method	for	S.	pneumoniae,	346 
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 There	 are	 a	 variety	 of	 characterisation	 techniques	 for	S.	pneumoniae	 including	361 
serotyping,	 MLST,	 PFGE,	 MLVA,	 Next	 Generation	 Sequencing	 and	 mass	362 
spectrometry.	363 
Traditional	characterisation	methods	364 
 Quellung	 serotyping,	 first	 developed	 in	 1902,	 is	 the	 “gold	 standard”	365 
characterisation	method	of	S.	pneumoniae.	366 
MLST	and	PFGE:	Current	“gold	standard”	genotyping	methods		367 




 With	 advancing	 technology,	 MLST	 can	 be	 combined	 with	 Next	 Generation	372 
Sequencing	to	quickly	process	samples.	373 
 A	 barcode	 can	 be	 assigned	 to	 bacterial	 species,	 enabling	 analysis	 of	 multiple	374 
bacteria	at	the	same	time.	375 
MLST	and	mass	spectrometry	376 
 MLST	 has	 also	 been	 combined	 with	 mass	 spectrometry	 as	 an	 alternative	377 
technique	to	quickly	process	samples.	378 
MLVA:	The	emerging	genotyping	method		379 
 An	 alternative	 bacterial	 fingerprinting	 method	 based	 on	 VNTRs	 instead	 of	380 
housekeeping	genes,	MLVA	was	developed	in	2005	for	S.	pneumoniae.	381 
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 A	 number	 of	 different	 MLVA	 protocols	 exist,	 and	 further	 investigation	 and	382 




MLST	 however	 modifications	 still	 continue	 as	 a	 robust	 method	 has	 not	 been	387 
universally	applied	that	can	ensure	complete	bacterial	profiles	are	achieved.	388 
Other	S.	pneumoniae	Characterisation	Techniques	389 




 Genotyping	methods	 can	 be	 applied	 in	 conjunction	with	 traditional	 serotyping	394 
methods.	395 
 MLVA	has	been	shown	to	be	highly	discriminatory,	cheaper	and	faster	than	the	396 
“gold	 standard”	 MLST	 and	 is	 therefore	 ideal	 for	 epidemiology	 studies	 of	 S.	397 
pneumoniae.	 Unfortunately,	 further	 investigation	 is	 required	 to	 determine	 a	398 
robust	and	universal	MLVA	method.	399 
 Genotyping	S.	pneumoniae	is	predicted	to	become	a	common	and	routine	process	400 
in	 diagnostic	 and	 clinical	 laboratories,	 not	 only	 research	 laboratories	 as	401 
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BOX‐02	 0	 279.0	 3 3
1_01	 286.0	 3 3 Deletion	in	boxA,	allele	contains	1	repeat
1	 322.5	 3 3
2_01	 330.0	 3 3 Deletion	in	boxA,	allele	contains	2	repeats
2_02	 359.0	 3 3 Deletion	in	boxC,	allele	contains	2	repeats
2	 366.0	 3 3
3	 411.0	 3 3
4	 454.5	 4 4
5	 499.0	 4 4
6	 545.2	 4 4
BOX‐03	 1	 393.0	 3 3
2	 435.4	 3 3
3	 480.0	 3 3
4_01	 490.0	 3 3 Deletion	in	boxA and	part	of	boxB,	allele	
contains	4	repeats	
4	 525.0	 3 3
5	 570.0	 3 3
5_01	 578.0	 3 3 Insertion	in	boxA,	allele	contains	5	repeats
6	 614.3	 4 4
7	 657.0	 4 4
8	 702.0	 4 4
9	 747.0	 5 2.5
9_01	 753.0	 2.5 5 To	be	sequenced
10	 789.0	 5 5
11	 834.0	 3 5
12_01	 860.7	 5 5 To	be	sequenced
12	 879.0	 5 5
13	 918.0	 5 5
14	 963.0	 5 5
15	 1003.2	 5.5 5.5
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Unambiguous	 Yes	 Yes	 Yes Yes Yes No	 [8,	 17,	
45,	52]	




















No No No	 [65]
Portable	 Yes	 Yes	 Yes Yes Yes Limited	 [8,	
17,47]	
Resolution	 High	 Unknown Unknown Unknown Unknown	 Good	 [17,	
47]	
Sensitivity	 High	 High	 High High High High	 [49]
Reproducibilit
y	
Good	 Good	 Unknown Unknown Unknown	 Unknown [8]
Technical	
demands	
High	 Minimal Unknown Unknown Unknown	 High	 [8,	52]
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0.827	 *	 0.779 0.607 	
Spneu17	 0.883	 *	 * 0.852 0.341	
Spneu19	 0.749	 	 * 0.674 	
Spneu25	
BOX‐13	
0.744	 *	 * 0.817 0.788 0.514	
Spneu26	 0.688	 *	 0.714 	
Spneu27	 0.575	 *	 0.561 0.682	
Spneu31	 0.763	 *	 0.695 0.139	
Spneu32	
BOX‐02	
0.629	 *	 0.685 0.598 	
Spneu33	
BOX‐04	
0.858	 *	 0.838 0.737 	
Spneu34	 0.598	 *	 * 0.682 0.470	
Spneu35	 0.561	 *	 0.572 	
Spneu36	 0.866	 	 * 0.793 	
Spneu37	
BOX‐12	
0.876	 *	 * 0.817 0.855 	
Spneu38	
BOX‐06	
0.616	 *	 0.700 0.557 	
Spneu39	 0.862	 *	 * 0.812 0.754	
Spneu40	
BOX‐01	
0.832	 *	 0.829 0.789 0.846	
Spneu41	 0.484	 *	 0.567 	
Spneu42	 0.739	 	 	
BOX‐11	 	 	 0.460 	
B4	 	 	 0.704	
B10	 	 	 0.634	
B12	 	 	 0.766	
*Loci	used	in	published	MLVA	technique	however	no	diversity	index	has	been	provided.	695 
